Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of CNTO6785 in active rheumatoid arthritis despite methotrexate
2012-003629-40Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CNTO6785 plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoint: ACR20 response. Started Nov 2012; status: completed.
02
Drugs
CNTO 6785
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003629-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003629-40.